HUE029111T2 - Rák kezelését célzó új készítmények és módszerek - Google Patents

Rák kezelését célzó új készítmények és módszerek Download PDF

Info

Publication number
HUE029111T2
HUE029111T2 HUE08830633A HUE08830633A HUE029111T2 HU E029111 T2 HUE029111 T2 HU E029111T2 HU E08830633 A HUE08830633 A HU E08830633A HU E08830633 A HUE08830633 A HU E08830633A HU E029111 T2 HUE029111 T2 HU E029111T2
Authority
HU
Hungary
Prior art keywords
cancer
cells
stat3
agent
cell
Prior art date
Application number
HUE08830633A
Other languages
English (en)
Inventor
Chiang Jia Li
Keith Mikule
Youzhi Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of HUE029111T2 publication Critical patent/HUE029111T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (2)

  1. Ä&x îsoeœséî célîô Φ mzïmÈmax ê$ mêmpmrôx
  2. 3 - KômÔÎÂüé, gmely ®ιν íis^öán^sgot foglár magéban ai afesrráns Jtafi útvonal aktivitás gétlésam, yoforpfoi egy második smtiy m aberráM $tat| j&vomt- aktivilMM kapcsolatos rákban szenvedő alanyok keodé.xére használatos. ahol aï első hatóanyag a kömks^ókbő! állő cäppoi^fedl: kerül; kivsIasxtáSMí ád'Rsidfőáífoblinmft^^ 2«8catlk'7vhibo-oaflo|äf:ä':h]furan'4f9*dlbn:f ^-acatíhy-fí-ucí^riafttlXJ^furáh-^S'^ilon, r^-^Q^tli'nigiflofn-4^*010rs,. valamint azok gyôgyâszstilag alfögadhatő sója vagy sxofvátja; a második hatóanyag pedig a következőket tactaImaxő csoportból kéről klyaiasztáára; pakgcaxel, ebötlnib, pnnltlmb, lapubolbv szorafooib, Isfbopiatfo, doxorubicin, docetaxel, gerncitafcm és etopozid. t, Ax i, Igénypont skarlntt hombibàôibï ahol a rák: a kdyetkezdkbol illő csoportból: kardi kiválasztásra: sítrIŐMk, fop Is nyakrák, tüdőrák, petefészekrák, hasnyálmlrigyrák, kotektáiis karclbőma,: pmtú^Wék^. •yasasejt-kareindiri^. melanoma, hepateeeriuláds kafoinőrna, méh nyak rák, .parkéma, agytumory gyomorrák, myetemamufoplex, leukémia ág Ifmfoma, :3, At í> igénypont szerinti; kombináció, ahol:1 az első hatóanyag 2>-ácotilU)gfto|23--b|íurán'-4J^ dión, lllétva annal |fÉgyàp^ii|gi#ô|arf'haté vagypoivátjs, fo Az 1. vagy 3. igénypont szerinti kombináció, shot a rák mefoszíatikus, az első vonalbeli rágkezeiőssei szemben raírikter vagy miggsausos, $ At L. igénypont szerinti kombináció, ahol: as ois# hatóanyag; 2“acabim^öp3*lí}fer|R4,^, dión, a második pádig gsmcltabim ahol sa eiső hatóanyag klsgaraláséré agy készítmény formájában karul sor.
HUE08830633A 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek HUE029111T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13

Publications (1)

Publication Number Publication Date
HUE029111T2 true HUE029111T2 (hu) 2017-02-28

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE08830633A HUE029111T2 (hu) 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek
HUE08830619A HUE027443T2 (hu) 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE08830619A HUE027443T2 (hu) 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok

Country Status (15)

Country Link
US (12) US8877803B2 (hu)
EP (6) EP2190429B1 (hu)
JP (16) JP5688840B2 (hu)
CN (6) CN101854802B (hu)
CA (4) CA2736564A1 (hu)
CY (3) CY1117604T1 (hu)
DK (4) DK2194987T3 (hu)
ES (3) ES2569215T3 (hu)
HK (3) HK1148906A1 (hu)
HR (3) HRP20160430T1 (hu)
HU (3) HUE029111T2 (hu)
PL (4) PL2194987T3 (hu)
PT (2) PT2200431T (hu)
SI (3) SI2194987T1 (hu)
WO (3) WO2009036101A1 (hu)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP2307367B1 (en) 2008-07-08 2014-09-24 Board of Regents, The University of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
EP2326329B1 (en) 2008-08-04 2017-01-11 Wyeth LLC Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
EP2506852A4 (en) 2009-12-04 2013-06-19 Univ Texas INTERFERONTHERAPIES IN COMBINATION WITH BLOCKING OF STAT3 ACTIVATION
TWI523851B (zh) 2009-12-28 2016-03-01 Yakult Honsha Kk 1,3,4-oxadiazole-2-carboxamide
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
MX360640B (es) 2010-03-01 2018-11-09 Tau Therapeutics Llc Star Diagnosis e imagenologia de cancer.
DK3108750T3 (en) * 2010-03-19 2018-10-22 1Globe Biomedical Co Ltd NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS
RU2571661C2 (ru) * 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
AU2011227023B2 (en) * 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
CN103153975B (zh) * 2010-08-24 2016-01-20 杭州益尔生物科技有限公司 用于疾病治疗的新型萘醌
US20130236473A1 (en) * 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
WO2012071648A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
EP2681203A4 (en) * 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
AU2012268400C1 (en) * 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2013039859A1 (en) * 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
JP6286358B2 (ja) * 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
EP2814480A4 (en) * 2012-02-17 2015-10-28 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd PROCESS FOR THE PREPARATION OF AQUEOUS SUSPENSIONS OF NANOPARTICLES OF 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANE ALIPHATIC ACID ESTERS DERIVATIVES
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103705926A (zh) * 2012-10-08 2014-04-09 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
BR112015025347A2 (pt) * 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2925944C (en) 2013-10-04 2023-01-10 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201609094A (zh) * 2014-01-27 2016-03-16 波士頓生醫公司 治療癌症之新穎方法
JP6695275B2 (ja) * 2014-02-07 2020-05-20 ボストン バイオメディカル， インコーポレイテッド ３−置換カルボニル−ナフト［２，３−ｂ］フラン誘導体又はその薬学的に許容される塩
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CA2943640A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
US20170266182A1 (en) * 2014-05-09 2017-09-21 The Brigham And Women's Hospital, Inc. Treatment of IgG-Immune Complex-Mediated Organ Damage
US10005752B2 (en) 2014-06-09 2018-06-26 Kyoto Pharmaceutical Industries, Ltd. Anticancer agent
CA2955177A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN113501826A (zh) 2015-01-08 2021-10-15 美国政府健康及人类服务部 作为tdp2的抑制剂的呋喃并喹啉二酮
EP3274346A1 (en) 2015-03-27 2018-01-31 Boston Biomedical, Inc. Water-soluble prodrugs
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
JP2018511642A (ja) * 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
WO2016168857A1 (en) * 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
EP3288552A1 (en) * 2015-04-27 2018-03-07 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
KR20180021697A (ko) * 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
JP6949726B2 (ja) * 2015-05-15 2021-10-13 ノバルティス アーゲー Ｅｇｆｒ変異癌を治療する方法
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP6810036B2 (ja) * 2015-07-17 2021-01-06 大日本住友製薬株式会社 ２−アセチル−４Ｈ，９Ｈ−ナフト［２，３−ｂ］フラン−４，９−ジオンの製造方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
US20190017054A1 (en) * 2016-01-07 2019-01-17 Luni Emdad Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
US11434229B2 (en) 2016-03-01 2022-09-06 Academia Sinica 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
JP6936214B2 (ja) 2016-03-25 2021-09-15 大日本住友製薬株式会社 ２−アルキルカルボニルナフト［２，３−ｂ］フラン−４，９−ジオンの関連物質の製造方法、及びその関連物質
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2019519573A (ja) 2016-06-28 2019-07-11 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018096401A1 (en) 2016-11-22 2018-05-31 Hitoshi Ban New naphtho[2,3-b]furan derivatives
JP7106563B2 (ja) * 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
BR112019011033A2 (pt) * 2016-11-30 2019-10-15 Tyme Inc composição, método para reduzir a proliferação celular em um indivíduo, método para tratar câncer em um indivíduo e kit
CN113769097A (zh) * 2017-01-22 2021-12-10 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
WO2018225062A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
CN111132614A (zh) * 2017-07-20 2020-05-08 路易斯安娜州立大学监测委员会，农业和机械学院 使用脉冲磁场梯度对恶性癌细胞的靶向渗透裂解
CN111295368A (zh) 2017-09-22 2020-06-16 大日本住友制药株式会社 化学活化型水溶性前药
EP3710050A4 (en) * 2017-11-16 2021-06-16 TyrNovo Ltd. COMBINATIONS OF IRS / STAT3 DOUBLE MODULATORS AND ANTI-PD-1 / PD-L1 AMBODIES FOR TREATMENT OF CANCER
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
CN111542598A (zh) * 2017-12-28 2020-08-14 株式会社钟化 多能干细胞聚集抑制剂
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
FI3770162T3 (fi) 2018-03-20 2023-06-02 Sumitomo Pharma Co Ltd Dihydrokromeenijohdannainen
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
CA3113408A1 (en) * 2018-09-18 2020-03-26 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
BR112021006898A2 (pt) * 2018-10-12 2021-07-20 1Globe Biomedical Co., Ltd. nova solução de combinação para tratar câncer refratário à quimioterapia
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
CA3136230A1 (en) * 2019-04-09 2020-10-15 Generos Biopharma Ltd. Pharmaceutical combination of pimozide and methotrexate and use thereof
US11564913B2 (en) * 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
US20220315551A1 (en) * 2019-06-14 2022-10-06 Sumitomo Dainippon Pharma Co., Ltd. 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
CA3158371A1 (en) * 2019-11-20 2021-05-27 Dianqing Wu Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
AU2020398177A1 (en) * 2019-12-05 2022-07-07 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
US20230192601A1 (en) * 2020-05-11 2023-06-22 Purdue Research Foundation Scaled-up synthesis of lomustine under control flow conditions
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
DE69131875T2 (de) * 1990-07-10 2000-06-15 Canon Kk Elektrophotographisches photoempfindliches Element
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
TW252136B (hu) * 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) * 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
ES2228587T3 (es) 1999-08-02 2005-04-16 F. Hoffmann-La Roche Ag Retinoides para el tratamiento de enfisema.
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1469733A4 (en) 2001-11-29 2008-07-23 Therakos Inc METHODS FOR PRETREATING A SUBJECT USING EXTRACORPOREAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS
WO2003075917A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
DK1344533T3 (da) 2002-03-15 2007-01-08 Natimmune As Farmaceutiske præparater, der omfatter mannosebindende lectin
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20060142271A1 (en) 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
EP1664070B1 (en) 2003-08-13 2008-08-13 University Of South Florida Methods for inhibiting tumor cell proliferation involving platinum complexes
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
JP4750716B2 (ja) 2003-12-02 2011-08-17 クリーブランド クリニック ファウンデイション フラジェリンを使用して放射線から保護する方法
JP4751336B2 (ja) * 2003-12-11 2011-08-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 細胞増殖性疾患を治療する化合
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
CA2563305A1 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
US7560462B2 (en) * 2004-07-02 2009-07-14 Icos Corporation Compounds useful for inhibiting CHK1
US20070249636A1 (en) * 2004-08-18 2007-10-25 Astrazeneca Ab Selected Fused Heterocyclics and Uses Thereof
MX2007005434A (es) * 2004-11-08 2007-07-10 Baxter Int Composiciones de nanoparticulado de inhibidor de tubulina.
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
US7807662B2 (en) 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
JP2008535785A (ja) * 2005-02-25 2008-09-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｔａｔ３の小分子阻害剤およびその使用
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006126505A1 (ja) 2005-05-26 2006-11-30 The University Of Tokyo Stat機能阻害剤およびその応用
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
NZ567266A (en) 2005-10-13 2010-09-30 Orchid Res Lab Ltd Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol)
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
JP2009521423A (ja) * 2005-12-24 2009-06-04 バイオチカ テクノロジー リミテッド 抗癌剤として有用な２１−デオキシマクベシン類似体
AU2007208494A1 (en) * 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Fluorinated arylamide derivatives
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
AU2007218966A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
CA2648003C (en) * 2006-03-31 2014-07-08 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
DK3108750T3 (en) 2010-03-19 2018-10-22 1Globe Biomedical Co Ltd NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS
RU2571661C2 (ru) 2010-03-19 2015-12-20 Бостон Байомедикал, Инк. Новые соединения и композиции для нацеливания на злокачественные стволовые клетки
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
US20180085341A1 (en) 2015-04-17 2018-03-29 Boston Biomedical, Inc. Methods for treating cancer
JP2018511642A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
WO2016168857A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
EP3288552A1 (en) 2015-04-27 2018-03-07 Boston Biomedical, Inc. Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
JP5701603B2 (ja) 2015-04-15
JP5938072B2 (ja) 2016-06-22
EP2200431B1 (en) 2016-07-20
CN101854937A (zh) 2010-10-06
US20210024482A1 (en) 2021-01-28
JP5872160B2 (ja) 2016-03-01
CN104586832B (zh) 2018-02-16
EP2190429A1 (en) 2010-06-02
US20110112180A1 (en) 2011-05-12
ES2569215T3 (es) 2016-05-09
HUE027657T2 (hu) 2016-11-28
EP2194987A4 (en) 2011-11-30
DK2194987T3 (en) 2016-08-15
CN101854802A (zh) 2010-10-06
JP2020143135A (ja) 2020-09-10
US20170197932A1 (en) 2017-07-13
CN105963289B (zh) 2021-02-26
JP2018131464A (ja) 2018-08-23
CA2736564A1 (en) 2009-03-19
US9732055B2 (en) 2017-08-15
US20150018410A1 (en) 2015-01-15
SI2200431T1 (sl) 2016-10-28
JP2014231522A (ja) 2014-12-11
US9834532B2 (en) 2017-12-05
JP2016065101A (ja) 2016-04-28
HK1148906A1 (en) 2011-09-23
ES2583010T3 (es) 2016-09-16
CA2736563C (en) 2016-01-26
JP6347795B2 (ja) 2018-06-27
EP2190429B1 (en) 2016-04-20
EP2194987A2 (en) 2010-06-16
US20210115006A1 (en) 2021-04-22
JP2010539095A (ja) 2010-12-16
US20100310503A1 (en) 2010-12-09
US20190135773A1 (en) 2019-05-09
EP2190429A4 (en) 2011-12-14
JP2016094465A (ja) 2016-05-26
CA2736532C (en) 2018-03-20
JP5688840B2 (ja) 2015-03-25
JP2016147906A (ja) 2016-08-18
JP2019073560A (ja) 2019-05-16
CY1117604T1 (el) 2017-04-26
CA2736563A1 (en) 2009-03-19
CN101854930A (zh) 2010-10-06
HRP20160430T1 (hr) 2016-05-20
EP3050566A3 (en) 2016-11-30
CN101854802B (zh) 2014-12-03
DK2200431T3 (en) 2016-08-15
US20200039948A1 (en) 2020-02-06
CA2911990A1 (en) 2009-03-19
EP3067054A1 (en) 2016-09-14
WO2009036099A1 (en) 2009-03-19
US20180030022A1 (en) 2018-02-01
CY1118476T1 (el) 2017-07-12
JP2015034179A (ja) 2015-02-19
EP2200431A1 (en) 2010-06-30
SI2194987T1 (sl) 2016-10-28
CA2736532A1 (en) 2009-03-19
WO2009036101A1 (en) 2009-03-19
CN101854937B (zh) 2013-03-27
PL3067054T3 (pl) 2021-10-04
JP2020117547A (ja) 2020-08-06
JP2014221843A (ja) 2014-11-27
CN103288787A (zh) 2013-09-11
CA2911990C (en) 2018-03-20
CN101854930B (zh) 2016-05-04
DK3050566T3 (en) 2019-03-11
WO2009036059A2 (en) 2009-03-19
JP6106149B2 (ja) 2017-03-29
JP2010539098A (ja) 2010-12-16
PL2194987T3 (pl) 2017-01-31
HK1148942A1 (zh) 2011-09-23
US8877803B2 (en) 2014-11-04
ES2584904T3 (es) 2016-09-30
EP3067054B1 (en) 2020-12-30
CY1117833T1 (el) 2017-05-17
HK1148943A1 (en) 2011-09-23
CN104586832A (zh) 2015-05-06
DK2190429T3 (en) 2016-05-30
US20190263768A1 (en) 2019-08-29
US20180030021A1 (en) 2018-02-01
SI2190429T1 (sl) 2016-10-28
EP3058941B1 (en) 2019-05-22
JP2010539097A (ja) 2010-12-16
EP3050566A2 (en) 2016-08-03
US10851075B2 (en) 2020-12-01
HRP20160625T1 (hr) 2016-08-12
PL2190429T3 (pl) 2016-09-30
JP6358659B2 (ja) 2018-07-18
US10377731B2 (en) 2019-08-13
CN103288787B (zh) 2016-08-03
JP5925849B2 (ja) 2016-05-25
HRP20160949T1 (hr) 2016-10-07
HUE027443T2 (hu) 2016-10-28
EP3058941A1 (en) 2016-08-24
PT2194987T (pt) 2016-08-05
EP2200431A4 (en) 2011-12-21
PT2200431T (pt) 2016-08-03
US9745278B2 (en) 2017-08-29
JP2015038151A (ja) 2015-02-26
JP2018076349A (ja) 2018-05-17
EP3050566B1 (en) 2018-11-28
CN105963289A (zh) 2016-09-28
JP6346628B2 (ja) 2018-06-20
WO2009036059A3 (en) 2009-07-02
US20120252763A1 (en) 2012-10-04
EP2194987B1 (en) 2016-05-18
PL2200431T3 (pl) 2017-01-31
JP2016034976A (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
US10377731B2 (en) Compositions and methods for cancer treatment
JP6754071B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
ES2859699T3 (es) Composiciones y métodos novedosos para el tratamiento del cáncer